Literature DB >> 23348167

Comparison of partial matrixectomy and combination treatment (partial matrixectomy + phenol) in ingrown toenail.

Cengiz Isik1, Husamettin Cakici, Kamil Cagri Kose, Nadir Goksugur.   

Abstract

UNLABELLED: To compare only partial matrixectomy and combination techniques (partial matrixectomy + phenol application) in the treatment of patients with an ingrown toenail in terms of recurrence, residual pain level and time of return to daily activities.
METHODS: The study included 118 patients with moderately ingrown toenails who were unresponsive to conservative treatment together with severely ingrown toenail patients. Of these patients, 76 cases were treated with a partial matrixectomy technique and 42 patients received combination treatment. Patients having nail infection received preoperative oral antibiotics.
RESULTS: Of 118 patients, 87 were males and 31 were females. The disease relapsed in seven (9.2%) of the patients treated with the partial matrixectomy technique, and in two (4.8%) patients from the combination treatment group (p=0.5). No statistically significant difference was found between the groups in terms of return time to daily activities (p=0.5) nor in terms of residual pain (p=0.7).
CONCLUSIONS: Treatment costs and operation times of patients who underwent phenol application in addition to partial matrixectomy were found to be higher compared to only partial matrixectomy, however combined therapy was not found to be superior to only partial matrixectomy in terms of recurrence, post-op pain and return to daily activities.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23348167

Source DB:  PubMed          Journal:  Med Glas (Zenica)        ISSN: 1840-0132


  1 in total

1.  A Minimally-Invasive, Simple, Rapid, and Effective Surgical Technique for the Treatment of Ingrown Toenails: A Reminder of the Original Winograd Procedure.

Authors:  Jahyung Kim; Sanghyeon Lee; Jeong Seok Lee; Sung Hun Won; Dong Il Chun; Young Yi; Jaeho Cho
Journal:  Int J Environ Res Public Health       Date:  2021-01-01       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.